Professional Team

Dr. Siegel founded Ground Zero Pharmaceuticals, Inc. (GZP) in 1999 from his consulting firm, Ground Zero Strategics, Ltd. He currently serves as its President and CEO and is also the Chairman of the Board. Prior to GZP Evan served as Consultant and CEO to OXO Chemie Inc., Vice President, Regulatory Affairs and Bioethics for Medical Science Systems, Inc. (now Interleukin Genetics), and Director of Regulatory Consulting Services and Principal Regulatory Scientist for Quintiles, Inc., North Carolina. Dr. Siegel has also held regulatory affairs and executive positions at Astra and Syntex and was a Toxicology Reviewer at the US Food and Drug Administration, as well as Supervising Toxicologist and Chief of Special Services at the State of California’s Food and Drug Branch, Department of Health Services. He is the author of a number of published articles in peer-reviewed journals, the editor of books on drug development and author of chapters on nonclinical development, vaccine biotechnology, and quality assurance. He has a Master and Doctor of Philosophy degrees in Virology and Molecular Biology and is an Adjunct Professor in the School of Pharmacy and Centre for Integrated Preclinical Drug Development, University of Queensland, Australia. He is a member of the Lt. Governor’s Biotechnology Advisory Committee to the California Economic Development Commission.

Ms. Templeton specializes in the development of accounting and finance systems as well as the structure and execution of operational procedures, administration of human resource and benefit programs, and infrastructure building for small high technology firms. With over fifteen years in finance and operations, her experience includes management of financial and patient progress data streams from clinical trials, receipt of invoices and payments, development of project management SOPs and policies, and tracking of medical product development information from disparate sources. She also is the primary contact for all contracting with Ground Zero Pharmaceuticals, Inc. Ms. Templeton’s financial background includes designing and implementing the accounting systems for both OXO Chemie AG (a multinational pharmaceutical corporation) and Interleukin Genetics, Inc., formerly Medical Science Systems, Inc. (a biotechnology firm), in addition to several start-up companies. She has also developed financial auditing systems for clinical trial programs. In addition, Ms. Templeton has been involved with business plan creation and production for a venture capital firm.

Ms. Mages is an experienced Life Sciences Business Developer with extensive relationships and knowledge, within the Southern California, Midwest, and Australian pharmaceutical, biotech, and medical device industries, in Business-to-Business Sales. She is adept at creating, building, and maintaining business relationships through cold calling/emailing, networking, and strategic marketing.  In addition, she is a regular attendee at BIO US, BIO Europe, AusBiotech conference, SoCal BIO, and many other annual life science conferences.  Previous roles have included business development leader and recruiter at Real Life Sciences and the Allegis Group.  She holds a BBA in Marketing from the University of Wisconsin, Milwaukee, completed an International Business program from Griffiths University in Queensland, Australia, and received a Regulatory Affairs Certificate: Medical Devices and Pharmaceuticals (Dual) completed through the Regulatory Affairs Certificate Program at RAPS University.